BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma

Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...

September 15, 2025 | News

Pulnovo Medical Secures Dual FDA IDE Approvals and CMS Coverage for PADN Clinical Trials in the U.S.

Pulnovo Medical, a globally recognized leader in medical devices for pulmonary hypertension (PH) and heart failure (HF), is proud to announce that its PADN...

September 15, 2025 | News

Mednovo Doses First Patient in Phase III Trial of Targeted Radiotherapeutic for GEP-NETs

Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodot...

September 12, 2025 | News

Kazia’s Paxalisib Disrupts Circulating Tumour Cell Clusters in HER2-Positive Metastatic Breast Cancer Study

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program...

September 12, 2025 | News

Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...

September 12, 2025 | News

Telix Doses First Patient In Phase 3 BiPASS™ Trial Evaluating Illuccix® And Gozellix® For Prostate Cancer Diagnosis

Telix Pharmaceuticals Limited announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix&re...

September 11, 2025 | News

Innorna completes Phase II enrollment for IN006, the first bivalent RSV mRNA vaccine

Innorna announced the completion of enrollment and vaccination in its Phase II clinical trial for IN006, the world’s first bivalent respiratory...

September 11, 2025 | News

XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours

XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...

September 10, 2025 | News

Takeda Wins U.S. FDA Approval to Expand VONVENDI Use in Adults and Children with Von Willebrand Disease

Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand D...

September 08, 2025 | Regulatory

AstraZeneca’s FLAURA2 Trial Confirms TAGRISSO Plus Chemotherapy Extends Survival in EGFR-Mutated Lung Cancer

FLAURA2 final overall survival analysis reinforces the favorable benefit-risk profile of this combination Results underscore TAGRISSO as 1st-line s...

September 08, 2025 | News

Taiwan’s Senhwa Biosciences Gains FDA IND Clearance for CX-5461 in MYC-Driven B-Cell Lymphomas

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has gran...

September 08, 2025 | News

Huadong Medicine Reports Promising Phase I Results for Novel ROR1-Targeting ADC HDM2005 in Lymphoma

Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") announced positive preliminary results from a Phase I study of HDM2005, an...

September 08, 2025 | News

Roche’s Vabysmo Demonstrates Strong One-Year Results in Asian Patients with Polypoidal Choroidal Vasculopathy

One-year SALWEEN results demonstrate robust efficacy, extended durability and consistent safety in patients with polypoidal choroidal vasculopathy (PCV),...

September 08, 2025 | News

Medidata eCOA Named Highest Leader in Everest Group’s 2025 Life Sciences PEAK Matrix® Assessment

Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by up to 50% compared to ...

September 05, 2025 | News

Stay Connected